NCT05529797 is a NA clinical trial of Veovita-VR in Depression, sponsored by Gaia AG.

Who is sponsoring NCT05529797?

NCT05529797 is sponsored by Gaia AG.

What drugs are being tested in NCT05529797?

Interventions in NCT05529797: Veovita-VR.

What condition does NCT05529797 study?

NCT05529797 studies Depression.

Is NCT05529797 still recruiting?

NCT05529797 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05529797

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a Single Virtual Reality Exposure on Depressive Symptoms (Veovita-VR)

Completed NA Last updated 15 June 2023

What this trial tests

NA trial testing Veovita-VR in Depression in 128 participants. Completed in 25 May 2023.

Timeline

1 September 2022

Primary endpoint
25 May 2023

25 May 2023

Quick facts

Lead sponsor	Gaia AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	1 September 2022
Primary completion	25 May 2023
Estimated completion	25 May 2023
Sites	1 location across Germany

Drugs / interventions tested

Veovita-VR

Conditions studied

Depression — all drugs for Depression →

Sponsor

Gaia AG — full company profile →

Who can join

18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial aims to evaluate the effectiveness of a novel virtual reality (VR) intervention (Veovita-VR) designed to expose people with at least moderate depressive symptoms to positive emotional stimuli and positive behavioral activation, thereby reducing depressive symptoms. Therefore, 128 adults with at least moderate depressive symptoms (operationalized as a Patient Health Questionnaire (PHQ-9) score ≥ 10) will be recruited and randomized into two groups: (1) a control group that may undergo depression treatment (Care-as-Usual, CAU) and receive access to Veovita-VR 5 weeks post-baseline (i.e., CAU control group), or (2) to an intervention group that receives one Veovita-VR session immediately after randomization and may also use CAU. The primary endpoint is depressive symptom level as assessed with the Patient Health Questionnaire (PHQ-9) 4 weeks post-baseline. Additionally, depressive symptoms (PHQ-9) will be assessed 1 week post-baseline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other Gaia AG trials

Trials by the same sponsor.

NCT06529965 — Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM · NA · recruiting
NCT06601907 — Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder · NA · terminated
NCT06237166 — Evaluation of an Online Intervention for Female Sexual Dysfunction · NA · completed
NCT06243978 — Effectiveness of a Digital Health Application for Primary Hypertension (Liebria) · NA · recruiting
NCT06221930 — Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity D · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05529797 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gaia AG
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing